---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003985"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:25:16.618024+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma expands Phase 2 glioblastoma trial; adds sites, extends timeline through Jan 2026

## Summary
- Change Order with Theradex increases Phase 2 patients from 15 to 16 and sites from 4 to 6.
- Total budget limited to $5,308,294; covers activities through 31 January 2026.
- Protocol amendments versions 2.0 and 3.0 added; safety teleconferences expanded for medical monitor review.
- Two sites (UNC and Georgetown) activated earlier than anticipated, driving budget increase.

## SEC filing metadata
- accession: 0001493152-25-003985
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315225003985/0001493152-25-003985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315225003985/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003985
- JSON: https://secwatch.observer/filing/0001493152-25-003985.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003985.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.